⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12341575 | 1.00 | — | — | |
| SCHEMBL131906 | 1.00 | — | — | |
| SCHEMBL3184748 | 0.90 | — | — | |
| SCHEMBL4129000 | 0.90 | — | — | |
| SCHEMBL12341578 | 0.89 | — | — | |
| SCHEMBL12341577 | 0.89 | — | — | |
| SCHEMBL79602 | 0.89 | — | — | |
| SCHEMBL136646 | 0.89 | — | — | |
| SCHEMBL1116025 | 0.89 | — | — | |
| SCHEMBL3755785 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 825 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3595715-B1 | RNA VACCINE AND IMMUNE CHECKPOINT INHIBITORS FOR COMBINED ANTICANCER THERAPY | CureVac SE (DE) | 2026-05-27 | — | — | EP | claimed |
| EP-4719469-A1 | COMBINATION CONTAINING AN MRNA VACCINE OR AN MRNA ENCODED THERAPEUTIC PROTEIN AND AN IMMUNE MODULATING MRNA FOR IMPROVED OR REDUCED IMMUNOGENICITY TO INCREASE EFFICACY | Imgen-T-Srl (IT) | 2026-04-08 | — | — | EP | claimed |
| EP-4692344-A1 | SELF-AMPLIFYING RNA CONSTRUCT AND USE THEREOF | Microuni Co., Ltd. (KR) | 2026-02-11 | — | — | EP | claimed |
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4599064-A1 | AN RNA APTAMER THAT BINDS TO ASP7967 OR AN ANALOGUE THEREOF | Okinawa Institute of Science and Technology School Corporation (JP) | 2025-08-13 | — | — | EP | claimed |
| US-20250213724-A1 | RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES | CureVac SE (DE) | 2025-07-03 | — | — | US | claimed |
| CN-119998451-A | RNA aptamer binding to ASP7967 or analog thereof | 学校法人冲绳科学技术大学院大学学园 | 2025-05-13 | — | — | CN | claimed |
| US-20250108102-A1 | NOVEL FRAGMENTED CRS PEPTIDE EXHIBITING IMMUNE ENHANCEMENT ACTIVITY, AND USE THEREOF | ZYMEDI CO., LTD. (KR) | 2025-04-03 | — | — | US | claimed |
| CN-119506395-A | Method and reagent for detecting fibrinogen content in whole blood or plasma | 上海基灵生物科技有限公司 | 2025-02-25 | — | — | CN | claimed |
| US-20250041352-A1 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF | SPINALCYTE LLC (US) | 2025-02-06 | — | — | US | claimed |
| US-11458195-B2 | Combination of vaccination and inhibition of the PD-1 pathway | CUREVAC AG (DE) | 2022-10-04 | — | — | US | claimed |
| EP-4058037-A1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | Figene, LLC (US) | 2022-09-21 | — | — | EP | claimed |
| US-20220282399-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, INC. (US) | 2022-09-08 | — | — | US | claimed |
| CN-109061132-B | System and method for determining diabetes risk based on biochemical marker analysis | 沃拉克有限公司 | 2022-08-26 | — | — | CN | claimed |
| WO-2022172962-A1 | RESIN COMPOSITION, CURED PRODUCT, LAMINATED BODY, CURED PRODUCT MANUFACTURING METHOD, SEMICONDUCTOR DEVICE, AND CYCLIZATION RESIN PRECURSOR | 富士フイルム株式会社 | 2022-08-18 | — | — | WO | claimed |
| WO-2022145356-A1 | RESIN COMPOSITION, CURED PRODUCT, LAMINATE, CURED PRODUCT MANUFACTURING METHOD AND SEMICONDUCTOR DEVICE | 富士フイルム株式会社 | 2022-07-07 | — | — | WO | claimed |
| WO-2022124849-A1 | NOVEL FRAGMENTED CRS PEPTIDE EXHIBITING IMMUNE ENHANCEMENT ACTIVITY, AND USE THEREOF | 재단법인 의약바이오컨버젼스연구단 | 2022-06-16 | — | — | WO | claimed |
| CN-112107680-B | mRNA-liposome complex and application thereof | 浙江智达药业有限公司 | 2022-04-08 | — | — | CN | claimed |
| EP-3527662-B1 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED TUMOUR ANTIGEN | CUREVAC AG (DE) | 2022-01-26 | — | — | EP | claimed |
| EP-3941585-A1 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF | Figene, LLC (US) | 2022-01-26 | — | — | EP | claimed |